Rezolute Q4 net loss narrows as R&D expenses fall

Overview

• U.S. rare disease drugmaker's fiscal Q4 net loss narrowed from prior year

• R&D expenses for fiscal Q4 declined, mainly due to lower manufacturing costs for ersodetug

• General and administrative expenses rose, driven by higher stock-based compensation and professional fees

Outlook

• Rezolute expects topline results from the upLIFT Phase 3 tumor HI study before end-2026

• Company awaits FDA feedback on the sunRIZE study for congenital HI

Result Drivers

• LOWER MANUFACTURING COSTS - Co said decrease in R&D expenses was primarily due to lower manufacturing costs for ersodetug

• HIGHER STOCK COMPENSATION AND FEES - Co attributed rise in G&A expenses to increased employee-related stock-based compensation and professional fees for future ersodetug commercial activities

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

• Wall Street's median 12-month price target for Rezolute, Inc. is $6.00, about 50% above its September 23 closing price of $4.00

Reuters Recommended Reads

• Sept 22 - Otsuka, Ionis' experimental ALS drug meets main goal in late-stage study

• Sept 24 - Acadia's Alzheimer's psychosis drug misses main goal of mid-stage study

• Sept 24 - Merck's drug for diabetes-related eye disease meets trial goal

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)